BRAF and familial atrioventricular septal defect: BRAFV600E is the most common driver mutation observed in over 50% of ECD cases [1], and the United States Food and Drug Administration (FDA) approved vemurafenib, a BRAF inhibitor, for BRAFV600E‐mutant ECD in a Phase 2 trial [7].